Tandutinib is a piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of Flt-3/Flk-2 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis. Tandutinib is an inhibitor of PDGFR-beta.
1. Brownlow, N., et al. 2008. Leukemia. 22: 1452-1453. PMID: 18185521
2. DeAngelo, D.J., et al. 2006. Blood. 108: 3674-3681. PMID: 16902153